The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.50
Bid: 31.00
Ask: 32.00
Change: 0.25 (0.80%)
Spread: 1.00 (3.226%)
Open: 31.25
High: 31.75
Low: 31.25
Prev. Close: 31.25
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PSAs, Issue of Equity & Director/PDMR Dealings

14 Oct 2022 07:00

RNS Number : 8591C
Duke Royalty Limited
14 October 2022
 

14 October 2022

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Performance Share Awards ("PSAs")

Issue of Equity

Director/PDMR Dealings

 

New grant under LTIP

 

 

Duke Royalty Limited (AIM: DUKE), a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, announces that the Company's Remuneration Committee has approved the grant of a total of 3,954,700 conditional rights to acquire ordinary shares of no par value (PSAs) under the Company's Long-Term Incentive Plan ("LTIP"). The LTIP framework was detailed within the Company's Admission Document which was published on 20 March 2017 and was put into place post Admission.

 

PSAs for the financial year to 31 March 2022 have been granted are as follows:

 

Neil Johnson

1,411,800

Charlie Cannon Brookes

1,270,600

Other employees (non-PDMRs)

1,272,300

Total

3,954,700

 

The PSAs vest after a period of three years and are subject to various performance conditions outlined in the Company's admission document (and available on the Company's website) and set by the Remuneration Committee, all in accordance with the LTIP rules. The PSAs will be subject to performance conditions, (50 per cent. based on growth in total shareholder return ("TSR") and 50 per cent. on growth in total cash available for distribution per share ("TCAD per Share")). TSR can be defined as the returns generated by shareholders based on the combined value of the dividends paid out by the Company and the share price performance over the period in question.

 

Vesting of 2019 PSAs, transfer from EBT & Director/PDMR interests

 

The Company also announces that a total of 1,799,688 PSAs, previously granted under the Company's LTIP in relation to the financial year ended 31 March 2019, have vested, representing 75% of the PSAs granted at that time.

 

Following the various transactions detailed above, the following Directors / PDMRs have the following total interest in ordinary shares:

 

 

Director/PDMR

Total ordinary shares held

Neil Johnson (1)

5,629,173

Charlie Cannon Brookes (2)

8,167,530

 

 

(1) Mr Johnson is Abingdon Capital Corporation's sole voting shareholder which legally owns 2,123,149 ordinary shares included within this figure.

 

(2) Mr Cannon Brookes is the investment director and shareholder of Arlington Asset Management Limited ("Arlington"). This figure includes 4,000,000 ordinary shares legally owned by Arlington.

 

 

Total voting rights and EBT shares

 

In order to maintain an appropriate level of headroom within the Company's EBT, the Company has issued 1,382,688 new ordinary shares into the Duke Royalty Employee Benefit Trust ("EBT"), ownership of which shall be transferred, in part or in full, to individual beneficiaries, subject to achievement of the performance criteria following the vesting period. Application has been made for these 1,382,688 shares to be admitted to trading on AIM, which is expected to occur on 18 October 2022 ("Admission"). 

 

Following Admission and transfer of the 1,382,688 shares to LTIP beneficiaries, the Company will have 417,534,034 ordinary shares in issue admitted to trading on AIM, of which 9,773,000 will be held by the EBT. This figure (417,534,034) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to, their interest in the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

For further information, please contact www.dukeroyalty.com, or contact: 

 

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon Brookes / Hugo Evans

 

+44 (0) 1481 730 613

Cenkos Securities plc 

(Nominated Adviser and Joint Broker)

 

Stephen Keys / Callum Davidson / Julian Morse 

 

+44 (0) 207 397 8900

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

+44 (0) 207 523 8000

Sec Newgate (PR)

Elisabeth Cowell/ Richard Bicknell / Max Richardson

+44 (0) 20 3757 6880 

dukeroyalty@secnewgate.co.uk

 

 

Notifications of dealings by PDMRs:

 

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Neil Johnson

2.

Reason for notification

a)

Position/Status

Chief Executive Officer

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Grant of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

1,411,800

d)

Aggregated Information

n/a

e)

Date of transaction

Award date: 13 October 2022

f)

Place of transaction

Outside a trading venue

 

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Neil Johnson

2.

Reason for notification

a)

Position/Status

Chief Executive Officer

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Acquisition of ordinary shares following vesting of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

637,500

d)

Aggregated Information

n/a

e)

Date of transaction

13 October 2022

f)

Place of transaction

Outside a trading venue

 

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Charlie Cannon Brookes

2.

Reason for notification

a)

Position/Status

Executive Director

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Grant of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

1,270,600

d)

Aggregated Information

n/a

e)

Date of transaction

Award date 13 October 2022

f)

Place of transaction

Outside a trading venue

1.

Details of the person discharging managerial responsibilities/persons closely associated

a)

Name

Charlie Cannon Brookes

2.

Reason for notification

a)

Position/Status

Executive Director

b)

Initial notification/amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Duke Royalty Limited

b)

LEI

213800GUTKPSJ39SER44

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary shares of nil par value

GG00BYZSSY63

b)

Nature of transaction

Acquisition of ordinary shares following vesting of conditional performance share awards under LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

450,000

d)

Aggregated Information

n/a

e)

Date of transaction

13 October 2022

f)

Place of transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEBLBDGXDBDGDX
Date   Source Headline
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.